US-based pharmaceutical giant Eli Lilly and Company has announced plans to invest more than USD 1 billion in India over the coming years, marking one of the largest foreign investments in the country’s healthcare manufacturing sector in recent times.
Investment to strengthen India’s pharma ecosystem
The announcement was welcomed by Union Minister of Commerce and Industry Piyush Goyal, who highlighted India’s growing presence in the global healthcare ecosystem. In a post on X, Goyal said, “We welcome @EliLillyandCo’s $1bn investment in India! This reaffirms our nation’s position as a global hub for innovation, R&D, manufacturing, and healthcare solutions. Under PM @NarendraModi ji’s leadership, India has made remarkable progress in enhancing Ease of Doing Business and building global trust in its quality ecosystem.”
Expansion plans in Hyderabad
Eli Lilly India plans to expand contract manufacturing and establish a new Manufacturing and Quality facility in Hyderabad, aiming to improve access to innovative medicines globally. The investment will enhance manufacturing and supply capabilities to support the company’s evolving portfolio, particularly in areas such as diabetes, obesity, cancer, Alzheimer’s disease, and autoimmune disorders.
Officials stated that the new facilities will not only expand global supply operations but are also expected to create thousands of job opportunities for Telangana’s youth, further strengthening Hyderabad’s position as a global life sciences and pharmaceutical hub.
Government support and collaboration
The announcement followed a delegation from Eli Lilly meeting Chief Minister A. Revanth Reddy and Industries Minister D. Sridhar Babu at the Integrated Command Control Centre on Monday. Chief Minister Revanth Reddy expressed his support, stating, “Telangana means business. Hyderabad is a global city. Our government will support and welcome all industries looking to invest here.” He also assured full government support for future expansions, reinforcing Telangana’s commitment to fostering a conducive environment for global investors.
This latest investment comes shortly after the inauguration of Eli Lilly’s Global Capability Centre (GCC) in Hyderabad on August 4, signalling the company’s growing focus on India as a strategic manufacturing and innovation hub.
Impact on India’s healthcare manufacturing sector
Industry experts note that this move underscores India’s rising prominence in global pharmaceutical manufacturing. By investing heavily in state-of-the-art facilities, Eli Lilly aims to strengthen its global supply chain, support research and development, and expand patients’ access to advanced medicines.
The investment is expected to have a long-term positive impact on employment, skill development, and innovation in the region, while positioning India as a preferred destination for global pharmaceutical investments.